Antares Pharma Inc (NASDAQ:ATRS) was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 4,610,000 shares, a decrease of 10.0% from the August 30th total of 5,120,000 shares. Approximately 3.1% of the shares of the company are short sold. Based on an average daily volume of 892,000 shares, the days-to-cover ratio is currently 5.2 days.
Separately, BidaskClub lowered Antares Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $5.04.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Corrado Advisors LLC acquired a new position in shares of Antares Pharma in the second quarter valued at $26,000. Bank of Montreal Can bought a new stake in Antares Pharma in the second quarter valued at $45,000. Aperio Group LLC bought a new stake in Antares Pharma in the second quarter valued at $47,000. Alpine Woods Capital Investors LLC grew its position in Antares Pharma by 60.0% in the second quarter. Alpine Woods Capital Investors LLC now owns 16,000 shares of the specialty pharmaceutical company’s stock valued at $53,000 after acquiring an additional 6,000 shares during the period. Finally, Prudential Financial Inc. grew its position in Antares Pharma by 33.8% in the second quarter. Prudential Financial Inc. now owns 18,530 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 4,680 shares during the period. Institutional investors and hedge funds own 38.72% of the company’s stock.
Shares of NASDAQ ATRS traded down $0.03 during trading hours on Monday, reaching $3.26. The stock had a trading volume of 495,842 shares, compared to its average volume of 785,201. The business’s fifty day moving average is $3.39 and its two-hundred day moving average is $3.10. The company has a debt-to-equity ratio of 1.01, a current ratio of 3.46 and a quick ratio of 2.87. The company has a market cap of $532.39 million, a price-to-earnings ratio of -81.50 and a beta of 0.82. Antares Pharma has a twelve month low of $2.53 and a twelve month high of $3.96.
Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $28.43 million during the quarter, compared to analyst estimates of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%. Sell-side analysts forecast that Antares Pharma will post -0.08 earnings per share for the current fiscal year.
About Antares Pharma
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Recommended Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.